What does this research mean for the field?

Immune checkpoint inhibitor therapy produces high and durable response rates in both metastatic and locoregional mismatch repair-deficient gastroesophageal adenocarcinoma, suggesting that nonoperative management may be a viable option for selected patients with locoregional disease. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the response rates of ICI therapy in patients with dMMR gastroesophageal adenocarcinoma.

April 17, 2026

Immunotherapy Response in Microsatellite Instability–High Gastroesophageal Adenocarcinoma

Key Points

To evaluate the response rates of ICI therapy in patients with dMMR gastroesophageal adenocarcinoma.
Conducted a single-center cohort analysis
Utilized ICI therapy in metastatic and locoregional settings
Assessed response rates and durability of treatment
High response rates observed for ICI therapy
Durable responses noted particularly in locoregional disease
Indicates potential for nonoperative management in selected patients

Abstract

In this single-center cohort of dMMR GEA, ICI-based therapy demonstrated high response rates in both metastatic and locoregional settings. The durable responses in locoregional disease suggest the potential to consider nonoperative management in selected individuals. Further research is needed to improve prediction of ICI response and refine treatment strategies.

Immunotherapy Response in Microsatellite Instability–High Gastroesophageal Adenocarcinoma

Key Points

Abstract

Cite This Study